SIBN
VENTE TOTALE: 54 956 titres (~1 026 420,06 $ US)
- Insiders
- DUNN JEFFREY W, FRANCIS LAURA
- Total bought
- —
- Total sold
- $1,026,420
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-22
SIBN presents a moderately compelling event-driven setup: a solid earnings catalyst (15.2% revenue growth, EPS beat, raised guidance) supported by strong liquidity (score 85) and a credible 68% confidence level.
The first sentence of the analysis written for SIBN on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.6% | 79.0% | 78.8% | 85.2% | 88.4% | |
| Ebit Margin | -6.8% | -16.4% | -28.7% | -54.9% | -58.9% | |
| Ebitda Margin | -5.4% | -13.8% | -24.8% | -51.7% | -56.5% | |
| Operating Profit Margin | -11.1% | -21.1% | -33.8% | -56.0% | -57.3% | |
| Pretax Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Continuous Operations Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Net Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Bottom Line Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Current Ratio | 8.549 | 7.658 | 9.012 | 6.498 | 10.412 | |
| Quick Ratio | 7.208 | 6.660 | 8.149 | 5.682 | 9.732 | |
| Solvency Ratio | -0.265 | -0.418 | -0.621 | -0.976 | -0.971 | |
| Cash Ratio | 1.671 | 1.288 | 1.418 | 0.978 | 3.755 | |
| Price To Earnings Ratio | -44.818 | -18.693 | -18.575 | -7.598 | -12.988 | |
| Price To Earnings Growth Ratio | 1.084 | 0.556 | 0.504 | -1.624 | -0.928 | |
| Forward Price To Earnings Growth Ratio | 1.084 | 0.556 | 0.504 | -1.624 | -0.928 | |
| Price To Earnings Diluted Ratio | -44.818 | -18.693 | -18.575 | -7.598 | -12.988 | |
| Price To Earnings Diluted Growth Ratio | 1.084 | 0.556 | 0.504 | -1.624 | -0.928 | |
| Price To Book Ratio | 4.833 | 3.482 | 4.762 | 4.732 | 5.477 | |
| Price To Sales Ratio | 4.270 | 3.478 | 5.808 | 4.371 | 8.166 | |
| Price To Free Cash Flow Ratio | -94.397 | -25.363 | -30.424 | -9.092 | -16.031 | |
| Price To Operating Cash Flow Ratio | -1,271.072 | -46.790 | -43.103 | -11.167 | -18.622 | |
| Debt To Assets Ratio | 0.005 | 0.163 | 0.169 | 0.250 | 0.212 | |
| Debt To Equity Ratio | 0.006 | 0.224 | 0.230 | 0.401 | 0.301 | |
| Debt To Capital Ratio | 0.006 | 0.183 | 0.187 | 0.286 | 0.231 | |
| Long Term Debt To Capital Ratio | 0.001 | 0.175 | 0.176 | 0.264 | 0.206 | |
| Financial Leverage Ratio | 1.344 | 1.380 | 1.360 | 1.603 | 1.417 | |
| Working Capital Turnover Ratio | 1.082 | 0.907 | 0.913 | 0.773 | 0.496 | |
| Operating Cash Flow Ratio | -0.027 | -0.458 | -0.798 | -1.967 | -2.341 | |
| Operating Cash Flow Sales Ratio | -0.003 | -0.074 | -0.135 | -0.391 | -0.439 | |
| Free Cash Flow Operating Cash Flow Ratio | 13.465 | 1.845 | 1.417 | 1.228 | 1.162 | |
| Debt Service Coverage Ratio | -1.751 | -6.713 | -9.950 | -19.505 | -9.500 | |
| Interest Coverage Ratio | -4.227 | -10.247 | -13.556 | -21.145 | -9.631 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.715 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.603 | -0.331 | -0.480 | -1.056 | -0.977 | |
| Capital Expenditure Coverage Ratio | -0.080 | -1.184 | -2.399 | -4.382 | -6.188 | |
| Dividend Paid And Capex Coverage Ratio | -0.080 | -1.184 | -2.399 | -4.382 | -6.188 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -74.899 | -25.284 | -23.582 | -8.800 | -13.993 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.6% | ▲0.5% | ▼-2.6% |
| Ebit Margin | -6.8% | ▲9.7% | ▲26.4% |
| Ebitda Margin | -5.4% | ▲8.4% | ▲25.0% |
| Operating Profit Margin | -11.1% | ▲10.0% | ▲24.8% |
| Pretax Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Continuous Operations Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Net Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Bottom Line Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Current Ratio | 8.549 | ▲0.891 | ▲0.123 |
| Quick Ratio | 7.208 | ▲0.548 | ▼-0.278 |
| Solvency Ratio | -0.265 | ▲0.153 | ▲0.385 |
| Cash Ratio | 1.671 | ▲0.383 | ▼-0.151 |
| Price To Earnings Ratio | -44.818 | ▼-26.125 | ▼-24.284 |
| Price To Earnings Growth Ratio | 1.084 | ▲0.528 | ▲1.166 |
| Forward Price To Earnings Growth Ratio | 1.084 | ▲0.528 | ▲1.166 |
| Price To Earnings Diluted Ratio | -44.818 | ▼-26.125 | ▼-24.284 |
| Price To Earnings Diluted Growth Ratio | 1.084 | ▲0.528 | ▲1.166 |
| Price To Book Ratio | 4.833 | ▲1.351 | ▲0.176 |
| Price To Sales Ratio | 4.270 | ▲0.793 | ▼-0.948 |
| Price To Free Cash Flow Ratio | -94.397 | ▼-69.034 | ▼-59.336 |
| Price To Operating Cash Flow Ratio | -1271.072 | ▼-1224.282 | ▼-992.921 |
| Debt To Assets Ratio | 0.005 | ▼-0.158 | ▼-0.155 |
| Debt To Equity Ratio | 0.006 | ▼-0.218 | ▼-0.226 |
| Debt To Capital Ratio | 0.006 | ▼-0.177 | ▼-0.173 |
| Long Term Debt To Capital Ratio | 0.001 | ▼-0.174 | ▼-0.163 |
| Financial Leverage Ratio | 1.344 | ▼-0.036 | ▼-0.077 |
| Working Capital Turnover Ratio | 1.082 | ▲0.175 | ▲0.248 |
| Operating Cash Flow Ratio | -0.027 | ▲0.431 | ▲1.091 |
| Operating Cash Flow Sales Ratio | -0.003 | ▲0.071 | ▲0.205 |
| Free Cash Flow Operating Cash Flow Ratio | 13.465 | ▲11.620 | ▲9.642 |
| Debt Service Coverage Ratio | -1.751 | ▲4.962 | ▲7.733 |
| Interest Coverage Ratio | -4.227 | ▲6.020 | ▲7.534 |
| Short Term Operating Cash Flow Coverage Ratio | -0.715 | ▼-0.715 | ▼-0.572 |
| Operating Cash Flow Coverage Ratio | -0.603 | ▼-0.272 | ▲0.086 |
| Capital Expenditure Coverage Ratio | -0.080 | ▲1.103 | ▲2.766 |
| Dividend Paid And Capex Coverage Ratio | -0.080 | ▲1.103 | ▲2.766 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -74.899 | ▼-49.616 | ▼-45.588 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $858.0M | $581.4M | $806.6M | $465.1M | $736.2M | |
| Enterprise value | $816.9M | $583.9M | $812.3M | $483.9M | $713.2M | |
| EV / Sales | 4.07x | 3.49x | 5.85x | 4.55x | 7.91x | |
| EV / Op. cash flow | -1210.15x | -46.99x | -43.41x | -11.62x | -18.04x | |
| EV / Free cash flow | -89.87x | -25.47x | -30.64x | -9.46x | -15.53x | |
| EV / EBITDA | -74.90x | -25.28x | -23.58x | -8.80x | -13.99x | |
| Net debt / EBITDA | 3.77x | -0.11x | -0.17x | -0.34x | 0.45x | |
| Current ratio | 8.55x | 7.66x | 9.01x | 6.50x | 10.41x | |
| Income quality | 0.04x | 0.40x | 0.43x | 0.68x | 0.70x | |
| Graham net-net | $3 | $3 | $3 | $2 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 138.8% | 112.5% | 108.7% | 104.8% | 106.6% | |
| Working capital | $190.8M | $180.6M | $187.9M | $116.4M | $159.0M | |
| Invested capital | $213.2M | $203.0M | $206.6M | $136.0M | $173.2M | |
| Return on assets | -7.9% | -13.4% | -18.8% | -38.9% | -29.7% | |
| Operating ROA | -9.5% | -15.3% | -24.2% | -34.3% | -25.0% | |
| Return on tangible assets | -7.9% | -13.4% | -18.8% | -38.9% | -29.7% | |
| Return on equity | -10.7% | -18.5% | -25.6% | -62.3% | -42.1% | |
| Return on invested capital | -10.4% | -17.2% | -22.5% | -43.3% | -29.5% | |
| Return on capital employed | -10.5% | -17.3% | -22.7% | -43.7% | -29.8% | |
| Earnings yield | -2.2% | -5.3% | -5.4% | -13.2% | -7.7% | |
| Free cash flow yield | -1.1% | -3.9% | -3.3% | -11.0% | -6.2% | |
| Capex / Op. cash flow | -1246.5% | -84.5% | -41.7% | -22.8% | -16.2% | |
| Capex / Depreciation | 309.5% | 239.7% | 143.7% | 275.4% | 306.3% | |
| Capex / Sales | 4.2% | 6.3% | 5.6% | 8.9% | 7.1% | |
| SG&A / Sales | 82.0% | 90.2% | 101.8% | 128.5% | 131.9% | |
| R&D / Sales | 8.7% | 9.9% | 10.8% | 12.8% | 13.8% | |
| Stock comp / Sales | 12.7% | 15.5% | 17.3% | 21.7% | 18.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 54d | 60d | 58d | 71d | 58d | |
| Days payables outstanding | 41d | 68d | 57d | 146d | 112d | |
| Operating cycle | 356d | 342d | 309d | 473d | 460d | |
| Cash conversion cycle | 315d | 274d | 252d | 327d | 348d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+47.6%EV / Sales ▲+16.4%EV / EBITDA ▼-196.2%EV / Op. cash flow ▼-1163.158Earnings yield ▲+0.031
Profitability
Return on equity ▲+0.079Return on assets ▲+0.055Return on invested capital ▲+0.068Return on capital employed ▲+0.069Operating ROA ▲+0.058Income quality ▼-0.366Tax burden 0.000
Efficiency
Days sales outstanding ▼-5.608Days payables outstanding ▼-26.371Operating cycle ▲+13.928Cash conversion cycle ▲+40.299Capex / Sales ▼-0.021R&D / Sales ▼-0.012
Balance-sheet strength
Current ratio ▲+0.891Net debt / EBITDA ▲+3.880Working capital ▲+10189000.000Invested capital ▲+10216000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+16.5%EV / Sales ▼-48.6%EV / EBITDA ▼-435.2%EV / Op. cash flow ▼-1192.111Earnings yield ▲+0.055
Profitability
Return on equity ▲+0.314Return on assets ▲+0.218Return on invested capital ▲+0.191Return on capital employed ▲+0.193Operating ROA ▲+0.155Income quality ▼-0.663Tax burden 0.000
Efficiency
Days sales outstanding ▼-3.335Days payables outstanding ▼-70.756Operating cycle ▼-104.366Cash conversion cycle ▼-33.610Capex / Sales ▼-0.029R&D / Sales ▼-0.051
Balance-sheet strength
Current ratio ▼-1.863Net debt / EBITDA ▲+3.320Working capital ▲+31860000.000Invested capital ▲+40005000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-31 SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026 SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time.
- 2026-08-25 Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy? Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-24 Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here''s is How to Trade The mean of analysts'' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 2026-08-06 Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect? The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-08-05 SiBone Q2 Earnings Call Highlights SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.S. revenue increased 14.7% to $53.2 million. International revenue grew 25.9% to
- 2026-08-04 SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
- 2026-08-03 Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.
- 2026-08-03 SiBone Q2 Earnings Call Highlights SiBone NASDAQ: SIBN reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio.
- 2026-08-03 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
- 2026-07-20 SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026 SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time